Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.
Also called NCT04688723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT04688723
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Unknown status
Technical summary
Registry record NCT04688723. Randomized; no masking; primary purpose treatment. Start 2020-12-23 (actual); primary completion 2022-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
- Acronym
- RE-DUAL PCI
- Condition
- Coronary Artery Disease
- Condition
- Myocardial Ischemia
- Condition
- Myocardial Infarction
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Dabigatran + Ticagrelor
- Intervention (Drug)
- Dabigatran + clopidogrel
- Lead sponsor
- Zuyderland Medisch Centrum
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct04688723- Content hash
baaf9b5c081a43c45d66292a75d795233cdd8d8b44b7647bb6c6b17f266e0de5